SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2269Millennium Pharmaceuticals Seen Fairly Valued 11.15.04, 9:44 AM ET Piper JaffraIcebrg-11/15/2004
2268today's cibc presentation: re: 2704 - - has seen tumor shrinkage in multipsoftware salesperson-11/10/2004
2267Millennium Announces Webcast of R&D Day 2004 Presentations CAMBRIDGE, Mass.bob zagorin-11/9/2004
2266PROTECT Study Shows Equivocal Results by: mr_nose_hair 11/08/04 08:09 am Msg: 5Icebrg-11/8/2004
2265New Clinical Trial Data Showed the Addition of INTEGRILIN(R) (Eptifibatide) Injemanny t-11/8/2004
2264Kosan Enters KOS-953 and Velcade(TM) Combination Into Clinic Monday November 8, Icebrg-11/8/2004
2263The fact that the first efficacy parametre detailed in the PR came out in favor former_pgs-11/7/2004
2262This is mystifying. I cannot get away from the impression that they are trying tIcebrg-11/7/2004
2261The results from the coronary flow reserve are disappointing. But myocardial performer_pgs-11/7/2004
2260Some results from PROTECT. Generally looks quite good for I. Any views on whetIan@SI-11/6/2004
2259[Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostuck-11/5/2004
2258Again, using the link you provided for ASH abstracts . . . Using "bortetuck-11/5/2004
2257[Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma]tuck-11/4/2004
2256>>CAMBRIDGE, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Millennium Pharmaceuttuck-11/2/2004
2255FDA Grants VELCADE(R) (bortezomib) for Injection Fast Track Status for Relapsed manny t-11/2/2004
2254Progenics and Cytogen Announce Award of $7.4 Million in NIH Grants for Prostate Icebrg-11/2/2004
2253GS: MLNM(IL/N):Modest rev. grwth make `06 profitability goal challenging. Revisemopgcw-10/31/2004
2252Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylaIcebrg-10/30/2004
2251Millenium Pharmaceuticals "neutral," target price reduced Friday, OctIcebrg-10/30/2004
2250[PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactuck-10/29/2004
2249UPDATE 1-Millennium Pharmaceuticals quarterly loss narrows (Updates with detailbob zagorin-10/29/2004
2248Sales, many thanks for your very helpful notes. I missed the live call, now I Ian@SI-10/28/2004
224710/28/04 cc notes 1. 3rd q highlights 11/16 is r&d day ( 9am -1 pm) r&software salesperson-10/28/2004
2246Millennium Reports Third Quarter 2004 Financial Results; Thursday October 28, 7:mopgcw-10/28/2004
2245Thalidomide SNDA ” etc Supplemental New Drug Application. CELG may look attracMiljenko Zuanic-10/27/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News